AstraZeneca enters big pharma deals with Par Pharmaceutical Companies for an exclusive U.S. supply and distribution agreement in which Par will distribute the authorized generic version of AstraZeneca's Atacand.

As part of the pharma deals, Par has begun shipping 4 mg, 8 mg, 16 mg and 32 mg strengths of candesartan cilexetil tablets.

According to IMS Health data, annual U.S. sales of Atacand are approximately $113 million.

Candesartan cilexetil is an angiotensin II receptor blocker indicated for the treatment of hypertension in adults and children 1 to < 17 years of age and the treatment of congestive heart failure.

Candesartan cilexetil reduces cardiovascular death and heart failure hospitalization.

Par Pharmaceutical Companies is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.

Daily news stories                                                                           

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with AstraZeneca

Report: Congestive Heart Failure Partnering

Report: Cardiovascular Partnering Terms and Agreements

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value 

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making        

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity                  

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity 

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now                                

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now 

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more 

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter